company background image
BEAM

Beam Therapeutics NasdaqGS:BEAM Stock Report

Last Price

US$59.56

Market Cap

US$4.1b

7D

-9.4%

1Y

-41.3%

Updated

17 Aug, 2022

Data

Company Financials +
BEAM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BEAM Stock Overview

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.

Beam Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beam Therapeutics
Historical stock prices
Current Share PriceUS$59.56
52 Week HighUS$116.91
52 Week LowUS$27.77
Beta1.76
1 Month Change2.67%
3 Month Change75.49%
1 Year Change-41.32%
3 Year Changen/a
5 Year Changen/a
Change since IPO217.65%

Recent News & Updates

Aug 09

Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M

Beam Therapeutics press release (NASDAQ:BEAM): Q2 GAAP EPS of -$1.02 misses by $0.05. Revenue of $16.65M beats by $7.21M. Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2022, as compared to $965.6 million as of December 31, 2021.

Shareholder Returns

BEAMUS BiotechsUS Market
7D-9.4%-2.0%1.1%
1Y-41.3%-23.0%-9.0%

Return vs Industry: BEAM underperformed the US Biotechs industry which returned -22.2% over the past year.

Return vs Market: BEAM underperformed the US Market which returned -8.9% over the past year.

Price Volatility

Is BEAM's price volatile compared to industry and market?
BEAM volatility
BEAM Average Weekly Movement13.0%
Biotechs Industry Average Movement12.3%
Market Average Movement7.6%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: BEAM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: BEAM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017476John Evanshttps://www.beamtx.com

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Beam Therapeutics Fundamentals Summary

How do Beam Therapeutics's earnings and revenue compare to its market cap?
BEAM fundamental statistics
Market CapUS$4.09b
Earnings (TTM)-US$233.99m
Revenue (TTM)US$76.92m

53.2x

P/S Ratio

-17.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BEAM income statement (TTM)
RevenueUS$76.92m
Cost of RevenueUS$232.13m
Gross Profit-US$155.22m
Other ExpensesUS$78.77m
Earnings-US$233.99m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.41
Gross Margin-201.80%
Net Profit Margin-304.21%
Debt/Equity Ratio0%

How did BEAM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BEAM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BEAM?

Other financial metrics that can be useful for relative valuation.

BEAM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue40.4x
Enterprise Value/EBITDA-24.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does BEAM's PB Ratio compare to its peers?

BEAM PB Ratio vs Peers
The above table shows the PB ratio for BEAM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average457.6x
VIR Vir Biotechnology
1.8x-40.0%US$3.4b
KRTX Karuna Therapeutics
21.5x57.4%US$8.7b
VSBC VitaSpring Biomedical
1803.3xn/aUS$3.4b
MRTX Mirati Therapeutics
4x45.8%US$4.5b
BEAM Beam Therapeutics
5.1x-14.9%US$4.1b

Price-To-Book vs Peers: BEAM is good value based on its Price-To-Book Ratio (5.1x) compared to the peer average (457.6x).


Price to Earnings Ratio vs Industry

How does BEAM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BEAM is expensive based on its Price-To-Book Ratio (5.1x) compared to the US Biotechs industry average (2x)


Price to Book Ratio vs Fair Ratio

What is BEAM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BEAM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BEAM's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BEAM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BEAM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BEAM's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Beam Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BEAM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BEAM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BEAM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BEAM's revenue (10.9% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: BEAM's revenue (10.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BEAM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Beam Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-39.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BEAM is currently unprofitable.

Growing Profit Margin: BEAM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BEAM is unprofitable, and losses have increased over the past 5 years at a rate of 39.1% per year.

Accelerating Growth: Unable to compare BEAM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BEAM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: BEAM has a negative Return on Equity (-29.24%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Beam Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BEAM's short term assets ($1.2B) exceed its short term liabilities ($212.3M).

Long Term Liabilities: BEAM's short term assets ($1.2B) exceed its long term liabilities ($405.9M).


Debt to Equity History and Analysis

Debt Level: BEAM is debt free.

Reducing Debt: BEAM has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable BEAM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: BEAM is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 9.9% per year.


Discover healthy companies

Dividend

What is Beam Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BEAM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BEAM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BEAM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BEAM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BEAM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

John Evans (44 yo)

5.33yrs

Tenure

US$13,911,975

Compensation

Mr. John M. Evans, MBA, is a Director at Prime Medicine, Inc. He serves as Chief Executive Officer and Director at Beam Therapeutics Inc. since January 2018 and served as its President since January 2018 u...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD13.91M) is above average for companies of similar size in the US market ($USD6.57M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BEAM's management team is considered experienced (3.9 years average tenure).


Board Members

Experienced Board: BEAM's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.


Top Shareholders

Company Information

Beam Therapeutics Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Beam Therapeutics Inc.
  • Ticker: BEAM
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$4.093b
  • Shares outstanding: 68.71m
  • Website: https://www.beamtx.com

Number of Employees


Location

  • Beam Therapeutics Inc.
  • 238 Main Street
  • 9th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.